Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02389465 · ClinicalTrials.gov registry record · Phase 4
Stress and Inflammation in Late-Life Depression
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 119
- Enrollment target
NCT02389465: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT02389465 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 119 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02389465, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 119 participants
- Enrollment target
Study Summary
Over 18% of Americans aged 65 years and older have depression. Recent evidence suggests that there is a link between depression and inflammatory disease. This study investigates the relationship between inflammation in the brain and depression. Comparing biological and psychological differences in depressed and non-depressed people allows researchers to find better ways to treat and prevent depression. All participants will have: neuropsychological tests, an EKG, a spinal tap, a blood draw, and, if depressed, given either an antidepressant coupled with an anti-inflammatory medication or an anti-depressant coupled with a placebo for six weeks. The investigators are trying to correlate brain function with depression levels and biomarkers from the blood and spinal fluid.
Interventions
- DRUG Escitalopram + Celecoxib
- DRUG Escitalopram + Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2014-08 |
| Est. Completion | 2022-07-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02389465
The ClinicalTrials.gov registry entry for NCT02389465 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Escitalopram + Celecoxib is the first listed.
NCT02389465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02389465 about?
NCT02389465 is a clinical study titled "Stress and Inflammation in Late-Life Depression". Over 18% of Americans aged 65 years and older have depression. Recent evidence suggests that there is a link between depression and inflammatory disease. This study investigates the relationship between inflammation in the brain and depression. Comparing biological and psychological differences in d...
What is the current status of trial NCT02389465?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 119 participants. The study started on 2014-08. Estimated completion is 2022-07-18.
What interventions are being tested in trial NCT02389465?
The interventions under investigation include: Escitalopram + Celecoxib (DRUG), Escitalopram + Placebo (DRUG).
Who is sponsoring clinical trial NCT02389465?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.